Latest news

Thumbnail image for CRT Pioneer Fund invests in BCL6 project

CRT Pioneer Fund invests in BCL6 project

The Cancer Research Technology Pioneer Fund is making its ninth investment in a project aiming to develop a new class of therapies for patients with diffuse large B-cell lymphoma - a sub-type of Non-Hodgkin Lymphoma (NHL).

9th December 2016

Thumbnail image for EU expands use of Novartis’ eye drug Lucentis

EU expands use of Novartis’ eye drug Lucentis

The treatment scope of Novartis' Lucentis has been expanded in Europe to include patients with visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD), or secondary to pathologic myopia (PM).

8th December 2016

Thumbnail image for AbbVie’s Venclyxto OK’d in Europe for CLL

AbbVie’s Venclyxto OK’d in Europe for CLL

Patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL) have gained a new treatment option after the European Commission issued a green light for AbbVie's Venclyxto.

8th December 2016

Thumbnail image for Lung cancer surgery survival rates on the rise

Lung cancer surgery survival rates on the rise

Survival rates following lung cancer surgery are continuing to rise as the number of operations to treat the disease increases, finds a new report published by the Royal College of Physicians (RCP) and the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS).

7th December 2016

Thumbnail image for AZ’ Tagrisso beats chemo in lung cancer trial

AZ’ Tagrisso beats chemo in lung cancer trial

Late-stage data show that AstraZeneca's Tagrisso extended the time lung cancer patients carrying a particular mutation lived without their disease worsening, potentially signalling a new standard of care in the second-line setting.

7th December 2016

Thumbnail image for NHS England announces cancer services boost

NHS England announces cancer services boost

NHS England's chief executive Simon Stevens has unveiled the first tranche of hospitals that will benefit from a major national investment in NHS radiotherapy machines, as well as a £200m fund to improve cancer services.

6th December 2016

Thumbnail image for Novo files once-weekly GLP-1 analogue semaglutide

Novo files once-weekly GLP-1 analogue semaglutide

Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.

6th December 2016

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download